152712-44-2

Basic information

• Product Name: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate
• Synonyms: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate;ethyl 3-(3,4-dihydro-2H-quinolin-1-yl)-2-oxo-propanoate
• CAS NO: 152712-44-2
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.28968
• EINECS: -0
• Mol File: 152712-44-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(152712-44-2)
• EPA Substance Registry System: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(152712-44-2)

Safety Data

• Hazardous Substances Data: 152712-44-2(Hazardous Substances Data)

Usage

General Description

Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is a chemical compound belonging to the ester class. It is a derivative of the dihydroquinoline ring, which is a heterocyclic aromatic compound. ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is used in organic synthesis and may have potential applications in medicinal chemistry. Its molecular structure features an ethyl ester group, a ketone group, and a dihydroquinoline ring, which gives it unique properties and reactivity. ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate may be of interest to researchers and industries working in the fields of chemical synthesis, pharmaceuticals, and materials science.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 70-23-5 ethyl Bromopyruvate 
• 856703-29-2 2-cyclopentyl-1, 2,3, 4-tetrahydroquinoline 

Downstream Products

• 124730-53-6 5,6-dihydro-4H-pyrrolo [3,2,1-ij]quinoline-1-carboxylic acid ethyl ester 
• 5840-01-7 5,6-dihydro-4H-pyrrolo-[3,2,1-ij]quinoline 
• 124730-56-9 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid 
• 905854-16-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-chloro-4-fluorophenyl)pyrrole-2,5-dione 
• 1000873-98-2 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 tivatinib 
• 905854-03-7 (+)-3(S),4(S)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-j]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-02-6 Tivantinib 
• 1000873-98-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 345264-02-0 (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)oxoacetic acid methyl ester 
• 345261-20-3 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dion 
• 1000873-98-2 (±)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-06-0 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(3-methoxyphenyl)pyrrole-2,5-dione 

Relevant articles and documents

COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

TRICYCLIC 1-[(3-INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS

The invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH2, O or S; R represents 1-3 substituents independently selected from H, (C1-4)alkyl, (C1-4)alky

Development of high-affinity 5-HT3 receptor antagonists. Structure- affinity relationships of novel 1,7-annelated indole derivatives. 1

On the basis of the structures of ondansetron and GR 65,630, its ring- opened C-linked methylimidazole analogue, novel 1,7-annelated indole derivatives were synthesized as potential 5-HT3 antagonists. Receptor binding studies show that all compounds display a high affinity for the 5- HT3 receptors. In both series annelation results in compounds being 7 and 4 times more potent than the references ondansetron and GR 65,630, respectively. Similar to ondansetron, the 1,7-annelated indoles show little stereoselectivity. The (-)-isomers are only slightly more potent than the (+)-isomers. The receptor binding profile of l-10-[(2-methyl-1H-imidazol-1- yl)methyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3,2,1-jk]carbazol-11-one hydrochloride (24b) (INN cilansetron) shows that the compound displays, besides a high affinity for 5-HT3 receptors (K(i) = 0.19 nM), a weak affinity for σ-receptors (K(i) = 340 nM), muscarine M1 receptors (K(i) = 910 nM), and 5-HT4 receptors (K(i) = 960 nM) and no affinity (K(i) ≥ 5000 nM) for all the other receptor types tested (n = 37). The new compounds fit the proposed necessary chemical template for binding: a heteroaromatic ring system, a coplanar carbonyl group, and a nitrogen center at well-defined distances. The enhanced potency of the annelated 1,7-indole derivatives indicates that the extra ring provides a favorable hydrophobic area for interaction with the 5-HT3 receptor site. In vivo cilansetron is more potent and induces less central side effects than ondansetron. At present cilansetron is in clinical trials.